(CercleFinance.com) – Nicox announces that future development of NCX 4251 will focus on dry eye disease, following encouraging post-hoc results from the Mississippi Phase 2b clinical study of NCX 4251 and a positive meeting with the US FDA.
The results, announced on November 30, suggest efficacy of the once-daily product in reducing dry eye symptoms in patients with a higher score for a key dry eye sign.
“We are finalizing the protocol for the next clinical study with our consultants and plan to initiate the next clinical study in 2023,” says Doug Hubatsch, EVP and chief scientific officer of the ophthalmology society.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
